Roche agrees to buy Therapeutic Human Polyclonals

SarahTurner

LONDON (MarketWatch) -- Swiss drugmaker Roche
RHHBY, +2.88%
said Monday that it acquired Therapeutic Human Polyclonals Inc., a privately-owned biotechnology company based in California and Germany, for $56.5 million in cash. THP is an emerging biotechnology company focused on human antibody technologies research. Roche said that it plans to fully integrate THP into the its site at Penzberg, Germany.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information. Intraday data
delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc.
All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More
information on NASDAQ traded symbols and their current financial status. Intraday
data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM)
from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is
at least 60-minutes delayed. All quotes are in local exchange time.